ALK and lung cancer: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and of these, approximately 2–7% are anaplastic lymphoma kinase (ALK), with the majority being of the nonsquamous subtype (3–5).